Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.38 |
| ▸ | TOP1 | P11387 | 1/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | PPARD | Q03181 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4996629 | 1.00 | LMNA (0.58) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL19741239 | 1.00 | LMNA (0.58) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL6700235 | 1.00 | LMNA (0.58) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL1668363 | 1.00 | LMNA (0.58) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL1964137 | 1.00 | LMNA (0.58) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL92729 | 1.00 | LMNA (0.58) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL11559107 | 0.97 | TDP1 (0.60) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL7789495 | 0.95 | LMNA (0.50) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL18264410 | 0.95 | LMNA (0.50) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL18877220 | 0.95 | LMNA (0.50) | LMNAL3MBTL1TDP1KDM4EPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7999006-B2 | Anticancer agents; mitogen-activated protein kinases (MEK) | EXELIXIS, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-20080166359-A1 | Methods of using MEK inhibitors | EXELIXIS, INC. | 2008-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080166359-A1 | Methods of using MEK inhibitors | BRAF, NRAS, KRAS | LMNA 3235/4885L3MBTL1 3691/4885TDP1 2192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.